AstraZeneca’s GALAXY Studies And Plans For Crestor’s Ongoing Development
This article was originally published in The Pink Sheet Daily
Company executives discuss on-going efforts to differentiate Crestor in the increasingly crowded cholesterol-lowering market.
You may also be interested in...
Expiration of the Lipitor patent puts tremendous pressure on AstraZeneca’s bestselling statin, Crestor, which accounts for 20% of total revenues. AstraZeneca insists the drug’s value proposition will enable it to withstand the onslaught, but analysts expect a gradual chipping away at market share.
Positive results from AstraZeneca’s outcomes trial of Crestor have all eyes on whether statin utilization will undergo a paradigm shift.
Company makes hay from Merck/Schering-Plough's failed Vytorin atherosclerosis trial.